Skip to main content

Advertisement

SpringerLink
Log in

Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

A Correction to this article was published on 12 May 2018

This article has been updated

Abstract

GO-MORE (NCT00975130) was a large open-label, multinational, multicenter, prospective phase 3 trial evaluating add-on therapy with golimumab in biologic-naïve patients with active rheumatoid arthritis (RA). The objective of this post hoc analysis was to examine regional differences in baseline disease activity and remission rates following golimumab treatment for RA. This was a planned, descriptive post hoc analysis of data from the GO-MORE trial. Baseline disease activity and remission were defined as moderate or severe based on EULAR criteria. This analysis included 3280 participants from the GO-MORE trial. All participants included in this analysis had high or moderate disease activity at baseline. At baseline, high disease activity was least common in Europe (71.0%), Canada (77.0%), and the Middle East (78.2%) and most common in Latin America (90.7%), South Africa (91.5%), and Asia (92.5%). Month 6 remission rates were highest in South Africa (29.1%), Europe (27.9%), and the Middle East (27.3%) and lowest in Canada (19.7%), Latin America (17.2%), and Asia (15.0%). Higher rates of remission in each geographical region generally corresponded with lower baseline disease activity. We suspect that access to care and implementation of the treat-to-target strategy were the most important determinants, but this apparent relationship needs to be confirmed in further studies that include a statistical analysis of prognostic indicators.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Change history

  • 12 May 2018

    The original publication contains two areas which require correcting. None of these errors change the results or conclusions of the article, but the authors wish to highlight the areas of change to the reader.

References

  1. Smolen JS, Aletaha D, Bijlsma JW et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631–637

    Article  PubMed  PubMed Central  Google Scholar 

  2. Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509

    Article  CAS  PubMed  Google Scholar 

  3. Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, Hsia EC, Xu W, Baratelle A, Beutler A, Rahman MU (2011) The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 63:1200–1210

    Article  CAS  PubMed  Google Scholar 

  4. Weinblatt ME, Bingham CO 3rd, Mendelsohn AM et al (2013) Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 72:381–389

    Article  CAS  PubMed  Google Scholar 

  5. Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374:210–221

    Article  CAS  PubMed  Google Scholar 

  6. Combe B, Dasgupta B, Louw I, Pal S, Wollenhaupt J, Zerbini CAF, Beaulieu AD, Schulze-Koops H, Durez P, Yao R, Vastesaeger N, Weng HH, on Behalf of the GO-MORE Investigators (2014) Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis 73:1477–1486

    Article  CAS  PubMed  Google Scholar 

  7. Fransen J, van Riel PL (2009) The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am 35:745–757 vii-viii

    Article  PubMed  Google Scholar 

  8. Vastesaeger N, Kutzbach AG, Amital H, Pavelka K, Lazaro MA, Moots RJ, Wollenhaupt J, Zerbini CAF, Louw I, Combe B, Beaulieu A, Schulze-Koops H, Dasgupta B, Fu B, Huyck S, Weng HH, Govoni M, Durez P (2016) Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. Rheumatology (Oxford) 55:1466–1476

    Article  CAS  Google Scholar 

  9. Alonso A, Gonzalez CM, Ballina J et al (2015) Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain. Reumatol Clin 11:144–150

    Article  PubMed  Google Scholar 

  10. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15

    Article  PubMed  Google Scholar 

  11. Putrik P, Ramiro S, Keszei AP, Hmamouchi I, Dougados M, Uhlig T, Kvien TK, Boonen A (2016) Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study. Ann Rheum Dis 75:540–546

    Article  PubMed  Google Scholar 

  12. Massardo L, Pons-Estel BA, Wojdyla D, Cardiel MH, Galarza-Maldonado CM, Sacnun MP, Soriano ER, Laurindo IM, Acevedo-Vásquez EM, Caballero-Uribe CV, Padilla O, Guibert-Toledano ZM, da Mota LM, Montufar RA, Lino-Pérez L, Díaz-Coto JF, Achurra-Castillo AF, Hernández JA, Esteva-Spinetti MH, Ramírez LA, Pineda C, Furst DE (2012) Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baseline. Arthritis Care Res (Hoboken) 64:1135–1143

    Google Scholar 

  13. Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar Pinheiro G, Lazovskis J, Hetland ML, Peets T, Immonen K, Maillefert JF, Drosos AA, Alten R, Pohl C, Rojkovich B, Bresnihan B, Minnock P, Cazzato M, Bombardieri S, Rexhepi S, Rexhepi M, Andersone D, Stropuviene S, Huisman M, Sierakowski S, Karateev D, Skakic V, Naranjo A, Baecklund E, Henrohn D, Gogus F, Badsha H, Mofti A, Taylor P, McClinton C, Yazici Y (2009) Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 68:1666–1672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Medical writing was provided by Dr. Phillip Leventhal (4Clinics, Paris, France) and paid for by MSD. Statistical support was provided by Dr. Ruji Yao (MSD). The GO-MORE study and this analysis were supported by MSD.

Author information

Authors and Affiliations

  1. Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, DurezAvenue Hippocrate 10, B-1200, Brussels, Belgium

    Patrick Durez

  2. Institute of Rheumatology (Revmatologicky Ustav), Na Slupi 4, 128 50, Praha 2, Czech Republic

    Karel Pavelka

  3. Instituto de Rehabilitacion Psicofisica de la Ciudad de Buenos Aires, Echeverria 955, C1428DQG, Buenos Aires, Argentina

    Maria Alicia Lazaro

  4. AGAR, UFM, 6 Avenida 7-55, zona 10, 01010, Guatemala City, Guatemala

    Abraham Garcia-Kutzbach

  5. University Hospital Aintree, Longmoor Ln, Liverpool, L9 7AL, UK

    Robert J. Moots

  6. Sheba Medical Center-Tel-Hashomer, Emek HaEla St 1, Ramat Gan, Israel

    Howard Amital

  7. MSD, Via Vitorchiano, 151, 00189, Rome, RM, Italy

    Marinella Govoni

  8. MSD, Clos du Lynx 5, 1200, Woluwe-Saint-Lambert, Belgium

    Nathan Vastesaeger

Authors
  1. Patrick Durez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karel Pavelka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Alicia Lazaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abraham Garcia-Kutzbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert J. Moots
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Howard Amital
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marinella Govoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nathan Vastesaeger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Durez.

Ethics declarations

Conflict of interest

P.D. received fees for participation in speakers’ bureaus for Bristol-Myers Squibb, Samsung, Pfizer, UCB, Mundipharma, Hospira, and Eli Lilly. K.P. received honoraria for speaking and consultations from AbbVie, Pfizer, Roche, Egis, Bristol-Myers Squibb, and MSD. M.D. and N.V. are employees of MSD. All other authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Durez, P., Pavelka, K., Lazaro, M.A. et al. Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial. Clin Rheumatol 37, 1417–1420 (2018). https://doi.org/10.1007/s10067-018-4074-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4074-6

Keywords

Search

Navigation